



Sheet 1 of 4

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1219P1C1

Serial No.

10/715,795

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Goddard, A. et al.

Filing Date

17 Nov 2003

Group

1646

## U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
OC	* 1	4,378,347	29.03.83	Franco, W.			

## FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes	No
OC	* 2	HEI 12-511867	11-2000	JAPAN				
OC	* 3	WO 93/18186	16.09.93	PCT				

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

	* 4	Abbass et al., "Altered expression of fibroblast growth factor receptors in human pituitary adenomas" <u>Journal of Clinical Endocrinology &amp; Metabolism</u> 82(4):1160-1166 (Apr 1997)
	* 5	Alitalo and Schwab, "Oncogene amplification in tumor cells" <u>Advances in Cancer Research</u> 47:235-281 (1986)
	* 6	Altschul and Gish, "Local Alignment Statistics" <u>Methods in Enzymology</u> 266:460-480 (1996)
	* 7	Arman et al., "Targeted disruption of fibroblast growth factor (FGF) receptor 2 suggests a role for FGF signaling in pregastrulation mammalian development" <u>Proc. Natl. Acad. Sci. USA</u> 95(9):5082-5087 (Apr 28, 1998)
	* 8	Armstrong et al., "Expression of fibroblast growth factor receptors in human leukemia cells" <u>Cancer Research</u> 52(7):2004-2007 (Apr 1, 1992)
OC	* 9	Aviezer et al., "Perlecan, basal lamina proteoglycan, promotes basic fibroblast growth factor-receptor binding, mitogenesis, and angiogenesis" <u>Cell</u> 79(6):1005-1013 (Dec 16, 1994)
	* 10	Baird and Bohlen, "Fibroblast Growth Factors" <u>Handbook of Exp. Pharmacol.</u> , Chapter 7, 95(1):369-418 (1990)
	* 11	Baselga et al., "HER2 Overexpression and Paclitaxel Sensitivity in Breast Cancer: Therapeutic Implications" <u>Oncology</u> (Supplement No. 2) 11(3):43-48 (March 1997)
	* 12	Baselga et al., "Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185HER2 Monoclonal Antibody in Patients With HER2/neu-Overexpressing Metastatic Breast Cancer" <u>J. Clin. Oncol.</u> 14(3):737-744 (Mar 1996)
	* 13	Bashkin et al., "Basic fibroblast growth factor binds to subendothelial extracellular matrix and is released by heparitinase and heparin-like molecules" <u>Biochemistry</u> 28(4):1737-1743 (Feb 21, 1989)
	* 14	Bishop, J., "Molecular themes in oncogenesis" <u>Cell</u> 64(2):235-248 (Jan 25, 1991)
	* 15	Bowie et al., "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions" <u>Science</u> 247:1306-1310 (1990)
	* 16	Ciruna et al., "Chimeric analysis of fibroblast growth factor receptor-1 (Fgfr1) function: a role for FGFR1 in morphogenetic movement through the primitive streak" <u>Development</u> 124(14):2829-2841 (Jul 1997)
	* 17	Colvin et al., "Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3" <u>Nature Genetics</u> 12(4):390-397 (Apr 1996)
	* 18	Dell and Williams, "A novel form of fibroblast growth factor receptor 2. Alternative splicing of the third immunoglobulin-like domain confers ligand binding specificity" <u>Journal of Biological Chemistry</u> 267(29):21225-21229 (Oct 15, 1992)

Examiner

Date Considered

7/15/04

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.